Abiomed
This article was originally published in The Gray Sheet
Executive Summary
Severe abdominal bleeding unrelated to the firm's AbioCor artificial heart caused the death of the first device recipient Nov. 30 after 151 days of use as part of an ongoing U.S. clinical trial, the firm states. Previous anticoagulant treatment also contributed to the death of the sixth AbioCor recipient from uncontrolled bleeding on Nov. 28. FDA cleared expansion of the trial from five to 10 patients on Nov. 26. Under the original IDE agreement, the U.S. AbioCor trial is expected to include three groups of five patients. The company expects to file a PMA in 2003...
You may also be interested in...
Abiomed To Show AbioCor Is Safe Enough For Healthier Patients
Abiomed is developing a smaller version of its artificial heart for the 65% of patients whose chest size is not large enough to accommodate the AbioCor device. The company recently began testing the Penn State Heart in animals and expectshuman implants to begin in 2004
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.